Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint

BACKGROUND: The CD47-SIRPα pathway acts as an important myeloid cell immune checkpoint and targeting the CD47/SIRPα axis represents a promising strategy to promote antitumor immunity. Several CD47-targeting agents show encouraging early activity in clinical trials. However, due to ubiquitous express...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhen-Hua, Li, Na, Mei, Xiao-Feng, Chen, Juan, Wang, Xiao-Ze, Guo, Ting-Ting, Chen, Gang, Nie, Lei, Chen, Yao, Jiang, Mei-Zhu, Wang, Ji-Teng, Wang, Hai-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905892/
https://www.ncbi.nlm.nih.gov/pubmed/35256517
http://dx.doi.org/10.1136/jitc-2021-004054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905892/
https://www.ncbi.nlm.nih.gov/pubmed/35256517
http://dx.doi.org/10.1136/jitc-2021-004054

Ejemplares similares